BidaskClub upgraded shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a buy rating to a strong-buy rating in a research report report published on Friday morning.

A number of other research analysts have also weighed in on KALV. Roth Capital initiated coverage on shares of Kalvista Pharmaceuticals in a research report on Tuesday, July 10th. They set a buy rating and a $20.00 target price for the company. ValuEngine raised shares of Kalvista Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, August 2nd. Zacks Investment Research raised shares of Kalvista Pharmaceuticals from a hold rating to a buy rating and set a $19.00 target price for the company in a research report on Wednesday, September 12th. Cantor Fitzgerald initiated coverage on shares of Kalvista Pharmaceuticals in a research report on Friday, September 21st. They set an overweight rating and a $32.00 price objective for the company. Finally, Stifel Nicolaus initiated coverage on shares of Kalvista Pharmaceuticals in a research report on Monday, October 15th. They set a buy rating for the company. One research analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. Kalvista Pharmaceuticals has a consensus rating of Buy and an average target price of $23.67.

Kalvista Pharmaceuticals stock remained flat at $$19.77 on Friday. 106,732 shares of the company’s stock were exchanged, compared to its average volume of 129,879. The firm has a market cap of $339.63 million, a price-to-earnings ratio of -12.92 and a beta of 3.02. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $23.97.

Kalvista Pharmaceuticals (NASDAQ:KALV) last released its earnings results on Friday, September 14th. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.14). The firm had revenue of $3.72 million for the quarter, compared to analyst estimates of $4.11 million. Kalvista Pharmaceuticals had a negative return on equity of 56.24% and a negative net margin of 132.38%. As a group, research analysts predict that Kalvista Pharmaceuticals will post -2.11 earnings per share for the current year.

In related news, Director Albert Cha acquired 1,058,824 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was acquired at an average price of $17.00 per share, with a total value of $18,000,008.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 49.10% of the stock is currently owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Interwest Venture Management Co. raised its position in shares of Kalvista Pharmaceuticals by 17.8% during the third quarter. Interwest Venture Management Co. now owns 388,766 shares of the specialty pharmaceutical company’s stock valued at $8,596,000 after buying an additional 58,824 shares during the last quarter. DRW Securities LLC raised its position in shares of Kalvista Pharmaceuticals by 37.3% during the second quarter. DRW Securities LLC now owns 20,600 shares of the specialty pharmaceutical company’s stock valued at $167,000 after buying an additional 5,600 shares during the last quarter. BlackRock Inc. raised its position in shares of Kalvista Pharmaceuticals by 203.8% during the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock valued at $132,000 after buying an additional 10,871 shares during the last quarter. Stanley Laman Group Ltd. raised its position in shares of Kalvista Pharmaceuticals by 48.3% during the second quarter. Stanley Laman Group Ltd. now owns 67,082 shares of the specialty pharmaceutical company’s stock valued at $545,000 after buying an additional 21,861 shares during the last quarter. Finally, Spark Investment Management LLC acquired a new position in shares of Kalvista Pharmaceuticals during the second quarter valued at about $108,000. 37.13% of the stock is owned by institutional investors and hedge funds.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: Return on Investment (ROI)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.